Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mevacor meeting

This article was originally published in The Tan Sheet

Executive Summary

FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees will convene Jan. 13-14 to consider J&J/Merck's NDA proposing an Rx-to-OTC switch of Mevacor (lovastatin 20 mg), the agency confirms Dec. 3. The meeting will begin at 8 am both days at the Holiday Inn, Bethesda, Md. J&J/Merck will present recently published data from its CUSTOM actual-use study in support of the switch (1"The Tan Sheet" Nov. 22, 2004, p. 8)...
Advertisement

Related Content

Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins
Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins

Topics

Advertisement
UsernamePublicRestriction

Register

PS097597

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel